Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized
For many people, recently popularized GLP-1 weight loss drugsknown by brand names like Ozempic, Wegovy, Mounjaro, and Zepboundseemed to offer a promising path forward
5 The two figures arent directly comparable because they come from different study designs and populations
"Ro's platform makes it easy for patients or providers to connect, enabling patients to ask a question, report a side effect or share progress with a provider any time they need," Manalac said in an emailed statement
Frustrated with diets that don't deliver